Alvotech initiates patient study for avt06, a proposed biosimilar for eylea®

Reykjavik, iceland (july 7, 2022) – alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of the company's confirmatory clinical study for avt06 (aflibercept), a biosimilar candidate to eylea®. the objective of the study is to compare avt06 and eylea® in terms of efficacy, safety, and immunogenicity in adult patients with neovascular (wet) age-related macular degeneration (amd).
ALVO Ratings Summary
ALVO Quant Ranking